WallStSmart

Everpure, Inc. (P)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Everpure, Inc. generates 22% more annual revenue ($3.94B vs $3.22B). WST leads profitability with a 16.9% profit margin vs 5.8%. P appears more attractively valued with a PEG of 1.53. WST earns a higher WallStSmart Score of 65/100 (C+).

P

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 4.5Value: 3.7Quality: 6.0
Piotroski: 3/9Altman Z: 1.16

WST

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for P.

WSTSignificantly Overvalued (-56.0%)

Margin of Safety

-56.0%

Fair Value

$157.79

Current Price

$314.50

$156.71 premium

UndervaluedFair: $157.79Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

P3 strengths · Avg: 9.0/10
EPS GrowthGrowth
139.7%10/10

Earnings expanding 139.7% YoY

Debt/EquityHealth
0.169/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
20.4%8/10

Revenue surging 20.4% year-over-year

WST5 strengths · Avg: 9.0/10
EPS GrowthGrowth
56.1%10/10

Earnings expanding 56.1% YoY

Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.119/10

Conservative balance sheet, low leverage

Operating MarginProfitability
21.7%8/10

Strong operational efficiency at 21.7%

Revenue GrowthGrowth
21.0%8/10

Revenue surging 21.0% year-over-year

Areas to Watch

P4 concerns · Avg: 3.5/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

Price/BookValuation
16.5x4/10

Trading at 16.5x book value

Profit MarginProfitability
5.8%3/10

5.8% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

WST2 concerns · Avg: 2.0/10
PEG RatioValuation
3.162/10

Expensive relative to growth rate

P/E RatioValuation
44.1x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : P

The strongest argument for P centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.

Bull Case : WST

The strongest argument for WST centers on EPS Growth, Altman Z-Score, Debt/Equity. Profitability is solid with margins at 16.9% and operating margin at 21.7%. Revenue growth of 21.0% demonstrates continued momentum.

Bear Case : P

The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 109.6x leaves little room for execution misses.

Bear Case : WST

The primary concerns for WST are PEG Ratio, P/E Ratio. A P/E of 44.1x leaves little room for execution misses.

Key Dynamics to Monitor

P carries more volatility with a beta of 1.45 — expect wider price swings.

WST is growing revenue faster at 21.0% — sustainability is the question.

P generates stronger free cash flow (112M), providing more financial flexibility.

Monitor COMPUTER HARDWARE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

WST scores higher overall (65/100 vs 57/100), backed by strong 16.9% margins and 21.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Everpure, Inc.

TECHNOLOGY · COMPUTER HARDWARE · USA

Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?